EP-1134: Proton therapy re-irradiation for large-volume recurrent high-grade gliomas von Amelio, D, Widesott, L, Maines, F, Fellin, F, Righetto, R, Vennarini, S, Rombi, B, Cianchetti, M, Dionisi, F, Donner, D, Rozzanigo, U, Schwarz, M, Chierichetti, F, Galligioni, E, Amichetti, M

Volltext

Impact of metabolic syndrome on clinical outcome of castration resistant prostate cancer (CRPC) patients treated with abiraterone and enzalutamide von Conteduca, V, Caffo, O, Galli, L, Maugeri, A, Scarpi, E, Maines, F, Chiuri, V E, Lolli, C, Kinspergher, S, Schepisi, G, Santoni, M, Santini, D, Fratino, L, Burgio, S L, Salvi, S, Menna, C, de Giorgi, U

Volltext

2-weekly docetaxel: issues for clinical practice von Massari, F, Maines, F, Bria, E, Galligioni, E, Caffo, O, Tortora, G

Volltext

Chemotherapy in metastatic renal cell carcinoma today? A systematic review von Buti, Sebastiano, Bersanelli, Melissa, Sikokis, Angelica, Maines, Francesca, Facchinetti, Francesco, Bria, Emilio, Ardizzoni, Andrea, Tortora, Giampaolo, Massari, Francesco

Volltext

Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders von Conteduca, V., Caffo, O., Scarpi, E., Sepe, P., Galli, L., Fratino, L., Maines, F., Chiuri, V.E., Santoni, M., Zanardi, E., Massari, F., Toma, I., Schepisi, G., Sbrana, A., Kinspergher, S., Cursano, M.C., Modonesi, C., Santini, D., Procopio, G., De Giorgi, U.F.F.

Volltext

861P - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders von Conteduca, V., Caffo, O., Scarpi, E., Sepe, P., Galli, L., Fratino, L., Maines, F., Chiuri, V.E., Santoni, M., Zanardi, E., Massari, F., Toma, I., Schepisi, G., Sbrana, A., Kinspergher, S., Cursano, M.C., Modonesi, C., Santini, D., Procopio, G., De Giorgi, U.F.F.

Volltext

Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with... von Caffo, O., Palesandro, E., Nole, F., Gasparro, D., Mucciarini, C., Aieta, M., Zagonel, V., Iacovelli, R., De Giorgi, U.F.F., Rossetti, S., Fratino, L., Ermacora, P., Nicodemo, M., Giordano, M., Sartori, D., Scapoli, D., Verri, E., Maines, F., Pappagallo, G., Aglietta, M.

Volltext

854P - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pt... von Caffo, O., Palesandro, E., Nole, F., Gasparro, D., Mucciarini, C., Aieta, M., Zagonel, V., Iacovelli, R., De Giorgi, U.F.F., Rossetti, S., Fratino, L., Ermacora, P., Nicodemo, M., Giordano, M., Sartori, D., Scapoli, D., Verri, E., Maines, F., Pappagallo, G., Aglietta, M.

Volltext

854PUpdated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts)... von Caffo, O, Palesandro, E, Nole, F, Gasparro, D, Mucciarini, C, Aieta, M, Zagonel, V, Iacovelli, R, Giorgi, U F F De, Rossetti, S, Fratino, L, Ermacora, P, Nicodemo, M, Giordano, M, Sartori, D, Scapoli, D, Verri, E, Maines, F, Pappagallo, G, Aglietta, M

Volltext

861PTime to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders von Conteduca, V, Caffo, O, Scarpi, E, Sepe, P, Galli, L, Fratino, L, Maines, F, Chiuri, V E, Santoni, M, Zanardi, E, Massari, F, Toma, I, Schepisi, G, Sbrana, A, Kinspergher, S, Cursano, M C, Modonesi, C, Santini, D, Procopio, G, Giorgi, U F F De

Volltext

Proton Therapy Reirradiation in Difficult-to-Treat Recurrent Glioblastoma von Amelio, D., Scartoni, D., Farace, P., Widesott, L., Lorentini, S., Vennarini, S., Fellin, F., Brugnara, S., Maines, F., Schwarz, M., Amichetti, M.

Volltext

New agents (nas) in metastatic castration-resistant prostate cancer (mcrpc): is there a sequence better than the others? von Maines, F., Caffo, O., Veccia, A., Galligioni, E., Trentin, C., Tortora, G., Bria, E.

Volltext

Prognostic and predictive role of 18F-choline (c) positron emission tomography (PET) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) treated with enz... von Veccia, A., Maines, F., Caffo, O., Trentin, C., Donner, D., Chierichetti, F., Sperduti, I., Bria, E., Galligioni, E.

Volltext

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions von Caffo, Orazio, Maines, Francesca, Rizzo, Mimma, Kinspergher, Stefania, Veccia, Antonello

Volltext

First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study von Bersanelli, M., Maines, F., Facchini, G., Gelsomino, F., Zustovich, F., Santoni, M., Verri, E., De Giorgi, U., Masini, C., Morelli, F., Vitale, M.G., Sava, T., Prati, G., Librici, C., Fraccon, A.P., Fornarini, G., Maruzzo, M., Leonardi, F., Caffo, O., Buti, S.

Volltext

P08.52 Proton therapy re-Irradiation in large-volume recurrent glioblastoma von Amelio, D., Widesott, L., Vennarini, S., Fellin, F., Maines, F., Righetto, R., Lorentini, S., Farace, P., Schwarz, M., Amichetti, M.

Volltext

Metabolic syndrome and inflammation in castration resistant prostate cancer (CRPC) patients (pts) treated with abiraterone (abi) and enzalutamide (enza) von Conteduca, V., Caffo, O., Galli, L., Maugeri, A., Scarpi, E., Maines, F., Chiuri, V., Lolli, C., Kinspergher, S., Schepisi, G., Santoni, M., Santini, D., Fratino, L., Burgio, S.L., Salvi, S., Menna, C., De Giorgi, U.

Volltext

Concurrent chemoradiotherapy (cCTRT) with weekly cisplatin (wCDDP) in locally advanced cervical cancer (LACC) patients (pts): a monoinstitutional experience von Murgia, V., Caffo, O., Caldara, A., Brugnara, S., Dipasquale, M., Ferro, A., Frisinghelli, M., Macrini, S., Maines, F., Daniela, M., Trentin, C., Valduga, F., Veccia, A., Galligioni, E.

Volltext

First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study von Bersanelli, M., Maines, F., Facchini, G., Gelsomino, F., Zustovich, F., Santoni, M., Verri, E., De Giorgi, U., Masini, C., Morelli, F., Vitale, M.G., Sava, T., Prati, G., Librici, C., Fraccon, A.P., Fornarini, G., Maruzzo, M., Leonardi, F., Caffo, O., Buti, S.

Volltext

Prognostic assessment in Abiraterone Acetate (AA) post-Docetxel (DOC) mCRPC cohort von Cavaliere, C., Caffo, O., Ortega, C., D'Aniello, C., Cecere, S.C., Di Napoli, M., Della Pepa, C., Crispo, A., Maines, F., Ruatta, F., Iovane, G., Montella, M., Pisconti, S., Pignata, S., Facchini, G.

Volltext